PA
CORT icon

Pineridge Advisors’s Corcept Therapeutics CORT Stock Holding History

Pineridge Advisors’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$4.16K Buy
+50
New +$3.62K ﹤0.01% 290

Other funds holding CORT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
PA
Parallel Advisors San Francisco, California $5.56B AUM 17.89% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Pineridge Advisors's CORT Position: Q3 2025 in Review

Pineridge Advisors opened a new position in Corcept Therapeutics (CORT) in Q3 2025: 50 shares worth $4.16K. The stake represents ﹤0.01% of the portfolio and ranks #290 among its holdings.

429 funds tracked by Wall St. Rank hold CORT as of Q3 2025.

  • Pineridge Advisors held 50 shares of Corcept Therapeutics worth $4.16K as of Q3 2025.
  • Corcept Therapeutics was a new Pineridge Advisors position in Q3 2025.
  • Corcept Therapeutics made up ﹤0.01% of Pineridge Advisors's portfolio in Q3 2025, its #290 holding.
  • 429 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q3 2025.

Based on Pineridge Advisors's 13F filing for Q3 2025, filed 4 Nov 2025.